Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Part of paid clinical trials in Brisbane, California.

Sponsor
InterMune
Study ID
NCT00057447
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Interferon Gamma-1b — DRUG
    100 or 200 mcg, SQ, 3x per week
  • Rituximab — DRUG
    375 mg per square meters, IV, 1x per week

Study Details

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland

Key Dates

Start date
Mar 31, 2003
Status verified
Oct 2007
Completion
Jun 30, 2004

Study Design

Enrollment
24 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes) [ Time Frame: 6 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Intermune IncBrisbaneCalifornia94005-

Find similar trials in Brisbane, CA

By research site
Intermune Inc· Brisbane, CA

Related Studies